|Day Low/High||16.58 / 17.27|
|52 Wk Low/High||16.56 / 69.76|
Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.
But what will be most important is whether support stays strong and the buyers show interest in the afternoon.
Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?
Here's how to trade six of the most active names on the market this afternoon.
Biotech companies show more energy than the rest of the market Monday.
CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.
Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.
Investors in Nektar Therapeutics saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 17th contracts and identified one put and one call contract of particular interest.
Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 1,041,247 share increase in total short interest for Nektar Therapeutics , to 9,398,731, an increase of 12.46% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.
Nektar Therapeutics (NKTR) said on Wednesday that it would sell 13 million shares of common stock at $13.50 each.
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational...
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.
Biotech stocks dominate our list of top charts today. Here are four to watch.
The big issue is if the market can build on Friday's jobs good news.
The bears are trying it out on the Bank of England news today, but they may get squeezed.
Computer programming has found that buying bad-news dips is a consistent winner.
Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a strong on high relative volume candidate
Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate
Doug Kass shares his thoughts on two auto stocks and Facebook.
Nektar Therapeutics (NKTR) stock is declining on Wednesday afternoon despite posting better-than-expected 2015 fourth quarter results after yesterday’s closing bell.
Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.
Doug Kass shares his views on the health of the banking sector and why he's buying biotech.
Doug Kass shares his views on why he's staying short of GM and MetLife despite steep declines in both stocks.
Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.